Autism spectrum disorders (ASDs) are pervasive developmental disorders that frequently involve a triad of deficits in social skills, communication and language. For the underlying neurobiology of these symptoms, disturbances in neuronal development and synaptic plasticity have been discussed. The physiological development, regulation and survival of specific neuronal populations shaping neuronal plasticity require the so-called 'neurotrophic factors' (NTFs). These regulate cellular proliferation, migration, differentiation and integrity, which are also affected in ASD. Therefore, NTFs have gained increasing attention in ASD research. This review provides an overview and explores the key role of NTFs in the aetiology of ASD. We have also included evidence derived from neurochemical investigations, gene association studies and animal models. By focussing on the role of NTFs in ASD, we intend to further elucidate the puzzling aetiology of these conditions.
Introduction
Approximately one child per 145 babies born in the United States will be diagnosed with some form of autism spectrum disorder (ASD) throughout their lifespan according to new estimates. 1 The differences noted in individuals with autism relate to development deficiencies of language, social interaction skills, repetitive and stereotyped movements and behaviours, hyperactivity, sensory disturbances, restricted interests and more rarely self-injury. 2, 3 Additional challenging aspects of ASD are comorbid disorders, such as epilepsy, 4 gastrointestinal problems 5 and sleep disorder. 6 The clinical presentation of autism is complex and variable, and therefore the term ASD is often used in this context. According to the ICD-10 (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision), ASD is described as a pervasive developmental disorder. Differentiation from other developmental disorders such as Rett syndrome, which show overlapping symptoms and a similar neurobiology to ASD, is not always easy, especially in the very early stages. Rett syndrome is a comparatively rare disorder with clinical proximity to ASD, but in contrast to ASD, a mono-genetic background can be defined in a majority of cases. 7 Rett syndrome, which affects girls only, is characterized by a profound learning disability following early normal development, with a consistent cluster of clinical features.
Although the aetiology of ASD is still not fully understood, twin and adoption studies suggest a strong genetic role in the manifestation of the disorder. [8] [9] [10] [11] Monozygotic twins show concordance rates of approximately 70-90%, whereas they are only 0-10% in dizygotic twins. 12, 13 However, in addition to genetic risk factors, there is evidence for an association with a variety of other conditions, including prenatal exposure to noxae such as alcohol, thalidomide or sodium-valproate as well as obstetric complications, pre-and post-natal brain damage, chromosomal aberrations such as fragile X-syndrome, tuberous sclerosis and 22q11.2 deletion syndrome among others. [14] [15] [16] One of the most consistent findings in autism is an increased brain size during development. [17] [18] [19] [20] Children with autism seem to undergo an abnormally accelerated brain growth during development. 18, 19, [21] [22] [23] It has been suggested that the formation of neuronal connections or the elimination of inappropriate connections does not proceed in the typical manner. Striking neuropathological findings, such as fewer Purkinje cells, smaller neuronal size and decreased dendritic branches in subjects diagnosed with ASD, have been reported for various brain regions, such as the cerebellum, [24] [25] [26] [27] [28] the hippocampus and the amygdale. 25, 26 Magnetic resonance imaging studies have also shown grey and white matter changes such as reduced neuronal and axodendendritic pruning in autism. [29] [30] [31] [32] [33] [34] Lately, inflammatory processes have also been discussed in the aetiopathology of autism. 28 A vast body of research has been undertaken in the last decade to elucidate the underlying pathophysiology of autism.
The development and maintenance of the central nervous system is influenced by several different mechanisms, one of the most prominent being neurotrophic factors (NTFs). [35] [36] [37] [38] [39] [40] [41] NTFs do not only have a key role in processes such as brain development and maintenance of neurons and their dentrites throughout life, but they also critically influence the formation and elimination of neuronal connections. They have been discussed in many studies as promising candidates responsible for part of the alterations seen in autism. [35] [36] [37] [38] [39] [40] [41] [42] [43] NTFs comprise a range of different protein superfamilies. At least six factors belong to the neurotrophin family: nerve growth factor (NGF), brain-derived growth factor (BDNF), neurotrophin (NT)-3, NT-4, NT-5 and NT-6. [44] [45] [46] [47] The neurotrophins are a family of closely related proteins that were first identified as survival factors for sympathetic and sensory neurons. 48 The core functions of neurotrophins during neurodevelopment include regulation of cell proliferation, migration and survival. They also modulate axonal and dendritic outgrowth, synapse formation and other neuroplastic processes. 49 Further neurotrophic superfamilies include neurokines such as ciliary NTF (CNTF) and leukaemia inhibitory factor (LIF), insulin-like growth factors (for example, IGF-1 and IGF-2), as well as the vast transforming growth factor-b (TGF-b) superfamily (for example, TGF-b1, -b2 and -b3), and their distant relative glial cell line-derived neurotrophic factor (GDNF). Additionally, there are a variety of other proteins that can at least partly exert an influence on neurotrophic functions, although they are not considered as NTFs themselves.
Furthermore, individual NTFs and their receptors are quite distinct and are subject to considerable changes in the course of neural development. 50, 51 The proteins of the neurotrophin family have a molecular weight of 13 kDa (NGF) to 27 kDa (BDNF, NT-3) and high isoelectric points (9-10.5). BDNF is one of the most abundant NTFs in mammalian brains.
The neurotrophin genes, like other peptide growth factors, encode a precursor peptide. 52, 53 Thus, the protein forms of neurotrophins exist in the human brain, both in the mature and in its precursor form (for example, proBDNF). The precursor form is secreted in both a basal and an activity-dependent fashion and is processed extracellularly to its mature form by proteolytic cleavage. [54] [55] [56] Only one frequent, nonconservative polymorphism in the human BDNF gene (dbSNP number rs6265) has been identified. This single-nucleotide polymorphism (SNP) at nucleotide 196 (G/A) produces an amino acid substitution (valine to methionine) at codon 66 (val66met).
Mature neurotrophins form stable, non-covalent dimers and bind with lower affinity to the p75 receptor and with higher affinity to receptors of the tyrosine kinase family (TrkA, B, C): BDNF and NT-4/5 bind TrkB and NT-3 binds TrkC and to a lesser extent TrkA. 46, 47, 57, 58 These interactions have generally been considered to be of high affinity. However, the binding of NGF to TrkA, and of BDNF to TrkB, is of low affinity, [59] [60] [61] [62] but can be regulated by receptor dimerization, structural modifications or association with the p75 receptor. 63, 64 Substrate binding leads to Trk dimerization and, therefore, to trans-autophosphorylation at two tyrosine residues (Tyr490 and Tyr785) in the cytoplasmatic domain of the receptor, activating the intracellular signalling cascade. 62 A key molecule interacting with these phosphotyrosine motifs is the Src homologous and collagen-like (Shc) adaptor protein. Shc links Trk signalling to two major signalling pathways: the Ras/Raf/ERK and the phosphatidylinositol-3 kinase (PI3K) pathway.
After activation, Shc interacts with Grb2. Regarding the Ras/Raf/ERK pathway, Grb2 then binds to SOS (son of sevenless). The Shc/Grb2/SOS complex attaches itself to the membrane through the interaction of Shc with the phosphorylated receptor, and mediates signalling to the Ras/mitogen-activated protein kinase pathway. 65, 66 The neurotrophins' ability to activate Raf depends on Rap1, a small endosomal G-protein. 67 The active Ras/Raf/ERK pathway influences, for example, transcription of the cyclic AMP-response element (CREB) transcription factor. Overall, this pathway has effects on the cell cycle, neurite outgrowth and synaptic plasticity. 68 Alternatively, Shc-bound Grb2 can activate PI3K through the Gab1 (Grb2-associated binder-1). PI3K can propagate cellular survival through Akt (protein kinase B) activities, 65 and also mitogenic signalling, cell survival, cytoskeletal remodelling and vesicular trafficking. 69 Binding of phospholipase-Cg to activate Trk constitutes an additional, Shc-independent pathway, resulting in the release of inositol phosphates and activation of protein kinase C. 65, 70 Through a different set of adaptor proteins, p75 signalling results in increases in Jun N-terminal kinase, nuclear factor-kB and ceramide. 71 P75 is capable of mediating apoptosis in a pathophysiological context, for example, after seizure or inflammation 72, 73 and-in oligodendrocytes-after spinal injury, 74 and also physiologically during neurodevelopment. 75 Surprisingly, pro-neurotrophins display higher affinities for the p75 56 and are more effective inductors of p75-dependent apoptosis. 56, 74 Thus, proteolytic cleavage seems to be an important mediator of neurotrophin biological activity, partly deciding on cellular fate.
Neurotrophins have been shown to produce increases in excitatory postsynaptic currents in hippocampal neurons. 76, 77 Both BDNF and NT-3 are able to induce long-term potentiation (LTP) in hippocampal neurons, a pivotal factor in the consolidation of memory and learning. Vice versa, BDNF or NT-4 knockout mice show impairments of LTP in the hippocampus. 78, 79 The molecular mechanisms of LTP induction by neurotrophins are still only poorly understood. Protein kinase inhibitors lead to impairments in Neurotrophic factors in autism T Nickl-Jockschat and TM Michel LTP, indicating that intracellular protein phosphorylation as well as phosphatidylinositol lipids and inositol-1,4,5 receptors are important for LTP. 80 NTFs in autism identified by serum level and genetic studies BDNF serum levels in autism It has been suggested that early BDNF hyperactivity may be involved in autism early in life. Nelson et al. 36 were the first to report higher BDNF levels in neonatal blood of children with ASD. The study compared a set of neurotrophin and neuropeptide serum levels in a group of children with ASD, another group of children with mental retardation (with no comorbidity of ASD) and a healthy control group, using recycling immunoaffinity chromatography. Along with neonatal concentrations of vasoactive intestinal peptide, calcitonin gene-related peptide and NT-4/5, BDNF concentrations were higher in children with ASD and in those with mental retardation without ASD than in control children. In 99% of children with autism and 97% with mental retardation, levels of at least one of these molecules exceeded those of all control children. 36 Concordant with these results, Connolly et al. 38 showed mean BDNF levels to be elevated in children with autism (mean age 5.9 ± 3.9) compared with controls. Notably, both IgG and IgM autoantibodies to BDNF were also elevated in children with ASD compared with controls. The latter findings were not idiosyncratic for ASD children: children with childhood disintegrative disorder and those with epilepsy also showed elevated IgG and IGM BDNF autoantibodies.
An overall increase of BDNF levels in autistic individuals was shown in a study by Miyazaki et al. 37 However, when interpreting the results of this study, one has to take into account that the age range was much larger in the autistic individuals (between 3 and 27 years) than in the control group (22-24 years) . A later study by Hashimoto et al. 39 showed that in young autistic male adults (age 21.1±2.1 years), the BDNF concentration was significantly lower than in neurotypical controls (22.2 years). The serum levels of BDNF in patients with autism were significantly lower than those of normal controls. Nevertheless, no correlations between BDNF levels and clinical variables in autistics were detected.
As BDNF was found to be frequently altered in ASD patients, one study focussed on its usability as an early biological marker for autism. 81 Besides a group with ASD patients, two comparison groups were enroled: children with mental retardation or developmental delay and unaffected controls randomly sampled from the California birth certificate files. They were frequency matched to autism cases on sex, birth year and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Austin, TX, USA). The concentration of BDNF in maternal midpregnancy and neonatal specimens was similar across all three study groups, questioning a connection between ASD pathogenesis and BDNF levels.
Recently, further analysis using Luminex technology indicated developmental trajectories for the concentrations of NTFs in ASD. 40 Concentrations of a set of neurotrophins, neuropeptides and cytokines were analysed from archived neonatal blood of children with later-diagnosed autism, Down syndrome, very preterm birth and term control infants as healthy controls. Results showed inhibitory substances in eluates from archived bloodspots, especially marked for measurement of BDNF. Concentrations in control subjects differed by age: BDNF rose markedly with age, whereas NT-3 and NT-4/5 concentrations were lower in adults than in newborn infants. Interleukin-8 concentrations were higher in newborn infants, preterm and term, than in adults. In samples from ASD children, NT-3 levels were significantly lower than controls and an increase in vasoactive intestinal peptide approached statistical significance. Concentrations of NT-4/5 and calcitonin-gene-related peptide were correlated in infants with ASD but not in Down syndrome or controls. 40 The results of another recent study suggested disturbances of BDNF level trajectories in ASD patients. 82 In healthy controls, serum BDNF concentration was found to be increased over the first several years and decreased slightly after reaching adulthood. No gender differences were reported. In the autism cases, mean levels were significantly lower in children 0-9 years old compared with teenagers or adults, or with age-matched healthy controls, indicating a delayed BDNF increase during development. The study also investigated circadian and seasonal fluctuations of BDNF serum concentrations. Circadian changes, but not seasonal changes, were found in serum levels of BDNF. In a separate study with adult rats, a circadian change in serum BDNF was found to be similar to that in the cortex, indicating a possible association with cortical functions.
In contrast to the variety of studies on serum levels of NTFs, only few studies have examined cerebrospinal fluid (CSF) levels. Riikonen and Vanhala 35 focussed on NGF levels in the CSF of patients with ASD and Rett syndrome, and used enzyme-linked immunosorbent assay for the determination of NGF. In ASD patients, mainly normal CSF NGF levels were found, whereas there were low to negligible values in Rett syndrome.
The cause for altered neurotrophin serum and CSF levels in ASD patients remains yet to be clarified. Given the putatively strong role of genetic factors in the aetiopathogenesis of ASD, it is necessary to take this into account when discussing the potential role of neurotrophins in this context. A study by Lang et al. 83 indeed showed that the well-characterized Val66Met SNP was shown to be associated with increased BDNF serum concentrations. This polymorphism, leading to a Met substitution for Val at codon 66 in the prodomain for BDNF, is common in human populations, with an allele frequency of 20-30% in Caucasian populations. 84 Therefore, further detailed investigations are needed to shed light on the role of a potential interplay between the Met allele and elevated serum BDFN levels in ASD.
However, studies on neurotrophin gene variants and autism are scarce.
Nishimura et al. 41 reported in their study that three, four-and five-SNP haplotypes were significantly associated with ASD. Val66Met is associated with alterations in brain anatomy and memory, but its relevance to clinical disorders is unclear. Nevertheless, it did not show any significant correlation with the disorder in their study. Moreover, the expression of BDNF mRNA in peripheral blood lymphocytes might differ from that in neurons. BDNF mRNA levels in the drug-naive ASD patients were increased compared with the healthy control group.
Some clues for an involvement of the BDNF gene in the aetiopathogenesis of ASD come from a study on the so-called 'WAGR' syndrome. This is a rare genomic disorder caused by deletion of the 11p14-p12 chromosome region. It comprises the following symptom clusters: Wilms tumour, aniridia, genitourinary malformations and mental retardation. A majority of WAGR patients have mental retardation and psychiatric comorbidities such as attentiondeficit/hyperactivity disorder and obsessive compulsive disorder, and > 20% of the patients also have features of autism. 85 Although the Wilms tumour/ genitourinary anomalies and aniridia are caused by deletion of Wilms tumour 1 (WT1) and paired box 6 (PAX6) genes, respectively, the genomic cause of mental retardation and autism in WAGR syndrome remains unknown. Using oligonucleotide arrays, a study aimed to characterize the 11p14-p12 deletions and to identify all the genes involved in each deletion. 86 Besides the already described WT1 and PAX6 deletions, a majority of patients enroled showed a deletion of the BDNF gene. It is tempting to speculate that the fact that the BDNF gene showed a deletion in many, but not all, patients might at least partly explain the fact that autism is a frequent, but not mandatory, part of the WAGR syndrome.
It is important to mention that both studies included only comparatively small sample sizes (n = 104 in the patient group of Nishimura et al. 41 and just 34 patients in Xu et al.
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). So far, association studies with larger sample sizes or even with independent replications showing a correlation between BDNF gene variants and autism do not exist. In this context, the study results cited above should be read with care and can serve at the most as first hints of an involvement of BDNF gene variants in the pathogenesis of autism.
Cytokines and TGF-b
For GDNF, so far, only data for CSF levels in Rett syndrome patients are available. No significant changes of GDNF levels in Rett syndrome patients were observed. 87 Besides members of the neurotrophin protein family as typical exponents of NTFs, serum levels of TGF-b1 have also been examined in ASD patients. TGF-b1 is a multifunctional ubiquitious polypeptide cytokine that was initially named for its ability to induce transformation to a mesenchymal phenotype in epithelial cultured cells. 88 In the human brain, TGF-b signalling is known to be involved in a variety of biological processes, including specification of developmental fate in embryogenesis for both neurons and glial cells and suppression of immune reactions. 89, 90 To the best of our knowledge, only two studies have examined TGF-b1 serum levels in autism. Okada et al. 91 were the first to investigate TGF-b1 serum levels in ASD patients. Serum levels of TGF-b1 in 19 male adult patients with autism and 21 age-matched male healthy subjects were measured using enzymelinked immunosorbent assay. The serum levels of TGF-b1 in the patients with autism were significantly lower than those of normal controls. However, there were no marked or significant correlations between serum TGF-b1 levels and other clinical variables, including ADI-R (Autism Diagnostic InterviewRevised) scores, Y-BOCS (Yale-Brown ObsessiveCompulsive Scale), aggression, Theory of Mind, and Intellectual Quotient in patients.
A second study was able to find similar results in children with ASD. 92 Plasma levels of active TGF-b1 were evaluated in 75 children with ASD compared with 68 controls. Children with ASD had significantly lower plasma TGF-b1 levels when compared with typically developing controls and also with children with developmental disabilities other than ASD, after adjusting for age and gender. In addition, there were significant correlations between psychological measures and TGF-b1 levels, such that lower TGF-b1 levels were associated with lower adaptive behaviours.
On a molecular genetic level, so far only one study has investigated correlations of TGF-b1 SNPs and ASD. 93 No significant SNP or haplotypic associations were observed for TGF-b1.
Insulin-like growth factors IGF-1 and IGF-2 are members of the insulin gene family, which stimulate cellular proliferation and differentiation during embryonic and postnatal development. [94] [95] [96] Both IGF-1 and IGF-2 are widely expressed in the central nervous system and exert their mitogenic influence through the membrane-bound tyrosine kinase IGF-1 receptor. with increased width of myelin sheath. 99 As overall brain volume in ASD patients is increased, 100 an involvement of IGF-1 in the pathogenesis of autism is plausible.
Riikonen et al. 99 determined IGF-1 and IGF-2 levels from CSF using radioimmunoassay in 25 children with autism and with a median age of 5 years 5 months, and in 16 age-matched comparison children without disability. IGF-1 and IGF-2 concentrations were further correlated with age of patients and head size. CSF IGF-1 concentration was significantly lower in patients with autism than in the control group. In children with autism < 5 years of age, the CSF concentrations were significantly lower than their age-matched comparisons. The head circumferences correlated with CSF IGF-1 in children with autism, but no such correlation was found in the comparison group. There was no difference between the two groups in CSF IGF-2 concentrations. It is important to mention that no patients with autism had macrocephaly.
Another study determined serum levels of IGF-1 and IGF-2, IGFBP-3 (IGF binding protein-3), GHBP (growth hormone binding protein) and of dehydroepiandrosterone and its sulphate in 71 boys between 4 and 8 years with ASD or autism and 59 age-matched control boys. 101 In contrast to the study of Riikonen et al., 99 subjects in the autism/ASD group had significantly greater head circumferences than controls, and also significantly higher weights than controls, whereas height did not differ significantly between groups. Levels of IGF-1, IGF-2, IGFBP-3 and GHBP in the group with autism/ASD were all significantly higher than in controls.
Urinary IGF-1 levels correlate with serum levels.
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A study used this noninvasive method, investigating the daily urinary excretion of IGF-1, epidermal growth factor (EGF) and IGFBP-3 in autistic children (n = 34, age 2-5 years) and age-matched control children (n = 29). The mean urinary IGF-1 level was lower in the autism group than the control group.
Other NTFs EGF is a common mitogenic factor with neurotrophic effects on cultured cortical neurons, stimulating neurite outgrowth in dopaminergic cells. 103 One study was able to show an association between an EGF haplotype and autism. 93 The authors focussed on the genes of three different cytokines: TGF-b1, EGF and hepatocyte growth factor. In a trio association study using DNA samples from families recruited into the Autism Genetic Resource Exchange, 252 trios with a male offspring scored for autism were selected for the study. Transmission disequilibrium tests revealed significant haplotypic association of EGF with autism. No association was found for TGF-b1 and hepatocyte growth factor.
Another study found that serum levels of EGF were altered in adult subjects with high-functioning autism. Serum levels of EGF in 17 male subjects with high-functioning autism and 18 age-matched healthy male subjects were measured. The serum levels of EGF in subjects with high-functioning autism were significantly lower than those of normal control subjects. There were no correlations between serum EGF levels and clinical variables in the subjects with autism. 104 Platelet-derived growth factor (PDGF) is mitogenic for many cell types. [105] [106] [107] The PDGF family is composed of four different polypeptide chains (A-D), encoded by four different genes. [108] [109] [110] PDGF chains assemble to a disulphide bond, homo-or hetero-dimer, thus forming the biologically active PDGF protein. 111 In neuronal stem cells, PDGF has been shown to direct neuronal differentiation, and it also supports neuronal cell survival and prevents cell death. 112 PDGF mediates its effects by binding to the high-affinity tyrosine kinase transmembrane receptors (PDGFa receptor and PDGFb receptor), leading in consequence to the activation of a variety of signal generators such as PI3K and ras. 113 Up to now, only one study has investigated PDGF subtype serum levels, comparing autistic male children aged 6-19 with an age-matched control group. 114 Serum levels of the PDGF-BB subtype were found to be significantly higher in the patient group. Remarkably, in the patient group, PDGF serum levels were significantly and positively correlated with the domain C scores of the ADI-R, which represent stereotyped patterns of behaviour. The same study found no association of altered vascular endothelial growth factor serum levels and autism.
Non-NTF susceptibility genes for autism and their influence on NTF levels and function
For many years, research has focussed on associating personality traits, behaviour and brain function with specific genetic variants. [115] [116] [117] [118] [119] [120] However, compelling molecular genetic evidence for an involvement of neurotrophins in ASD comes from functional analyses of established ASD susceptibility gene variants. Although these genetic variants do not directly affect genes of the NTF family, they often lead to alterations of NTF levels or to impairments of NTF functions. 121 
Caps2
Ca2 þ -dependent activator protein 2 (CAPS2, alternatively CADPS2) is a promising ASD candidate gene in the chromosomal 7q31 region, a replicated linkage region for ASD. 122 The CAPS2 protein is enriched on vesicular structures in the parallel fibre terminals of granule cells. CAPS2-asscociated vesicles contain BDNF and NT-3 in large quantity. Remarkably, induced overexpression of CAPS2 increases depolarization-induced BDNF and NT-3 release. 123 Thus, impaired CAPS2 function might lead to altered BDNF and NT-3 levels in autism.
Most data suggest that disruption of the CAPS2 gene in ASD patients is due to copy number variations. 122 In contrast to the more extensively studied SNPs, which affect only one base in the sequence of a given gene, copy number variations are larger mutations sized from one kilobase to several megabases.
A study by Sadakata et al. 124 reported an aberrant, alternatively spliced CAPS2 mRNA that lacks exon 3 (Caps2deltaexon3) in some patients (n = 16) with ASD. In a subsequent animal study using a mouse model, Sadakata et al. 125 tried to further characterize CAPS2 splice variants and identified six alternative splicing variants, CAPS2a-f. CAPS2c showed slightly decreased BDNF-releasing activity, which might be likely due to the C-terminal truncation of the PH domain in CAPS2. Thus, the previously mentioned human CAPS2 splicing variant found no homologue in mice.
As CAPS2 is considered a candidate gene for ASD and has been characterized as a neuronal activitydependent modulator of neurotrophin release, CAPS2 gene mutations might provide a contribution to altered neurotrophin activity in ASD patients. However, other ASD susceptibility gene variants also seem to impact neurotrophin activity.
MECP2
As the Rett syndrome (see above) has the advantage of a well-defined genetic cause in a majority of cases and its clinical presentation is close to autism, the study of this disorder might also provide valuable insight into ASD pathophysiology. In most patients, Rett syndrome is caused by mutations in the X-linked methyl-CpG-binding protein 2 (MECP2). 7, 126 MeCP2 is a chromatin-associated protein 127 that can both activate and repress gene transcription, 128, 129 and it is capable of both suppressing and inducing BDNF transcription. [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] Neuronal activity triggers MeCP2 phosphorylation, therefore leading to BDNF gene processing, whereas prevention of MeCP2 phosphorylation interferes with the ability of MeCP2 to regulate dendritic patterning, spine morphogenesis and the activity-dependent induction of BDNF transcription. 131 These results suggest a central role for MeCP2 in neural activity-dependent brain maturation that at least partly exerts its influence on synaptic plasticity through its effects on BDNF.
Molecular MeCP2/BDNF-related pathologies in autism are more complex than in Rett syndrome. Whereas MeCP2 mutations seem to be rare in ASD, 133 MeCP2 mRNA levels were found to be reduced in the absolute majority of ASD cortex samples. 134 Although a comprehensive explanation for reduced MeCP2 transcription rates still remains to be found, disrupted co-regulation of MeCP2 and EGR2 (early growth response gene 2) leads to an impaired positive feedback loop on transcription rates of both genes.
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EGR2 is one of the so-called immediate activity genes, a class of genes rapidly and transiently induced by neuronal activation and other cellular or extracellular stimuli without the necessity for de novo protein synthesis. 136 In turn, BDNF signalling was shown to enhance EGR2 transcription. 137 These data suggest a disordered MeCP2/EGR2/BDNF signalling cascade, leading in consequence to a disturbance of neuronal activity-dependent maturation. Hence, this hypothesis yet remains to be proven and does not offer further insight into the exact cause of this disturbance.
JARID1C
A single case report describes a novel missense mutation in the Jumonji AT-rich interactive domain 1C (JARID1C) gene. 138 Recent novel molecular evidence suggests that JARID1C is a histone demethylase specific for di-and trimethylated H3K4 (histone 3 lysine 4) and functions as a regulator of neuronal gene transcription. 139, 140 The JARID1C-regulated genes include BDNF. It has to be noted that up to now, only 14 cases of JARID1C mutations have been reported in ASD cases.
All previous findings taken together, there is mounting evidence for altered neurotrophin serum levels in ASD. Specific variants of ASD susceptibility genes could provide at least some explanations for the alterations found in the neurotrophin serum levels. Most animal models investigated suggest an interplay between BDNF and the studied behaviour.
Nonetheless, several important questions still need to be addressed. Neurotrophin levels are subject to developmental trajectories over the course of lifetime. 40, 51, 141 Apparently, more research on the course of neurotrophin trajectories in ASD should be carried out. Moreover, there seems to be a circadian rhythmicity of at least BDNF secretion. 82 It still needs to be clarified whether ASD patients show the same circadian secretion patterns as healthy controls. Therefore, the subjects have to be matched not only for age, but also for the time of day at which the blood sample was obtained.
Besides these central nervous action mechanisms of BDNF, altered peripheral modes of action also deserve to be mentioned, 142 although they are not a central point of view of this review.
Neuropsychology and imaging studies
Altered levels of NTFs and the functional and neuroanatomical consequences: lessons from neuropsychology and brain imaging Changes in both anatomical and/or functional cerebral connectivity have been reported frequently in ASD patients. 121, 143, 144 As neurotrophins are known to modulate axonal and dendritic outgrowth, synapse formation and other neuroplastic processes, 49 neurotrophin dysfunction might well exert an impact on both anatomical and functional aspects of brain connectivity. Thus, these changes in brain structure and function might reflect important pathophysiological consequences at least partially caused by altered neurotrophin levels and functionality. Findings in these fields will be discussed here as far as they relate to the topic of this review.
Until now, only very few studies on white matter abnormalities have been published, with a focus on regions possibly involved in ASD pathophysiology. 145 In one of the first studies using diffusion tensor imaging to determine anatomical connectivity in ASD patients, Barnea-Goraly et al. 146 found reduced anatomical connectivity in brain regions of social cognition such as the fusiform gyrus and the superior temporal sulcus as well as in regions associated with theory of mind tasks (ventromedial prefrontal cortex, anterior cingulate, temporo-parietal junction and amygdala). Subsequent studies found reduced anatomical connectivity of the callosum, 147 the frontal lobe 148 and the superior temporal gyrus. 149 Notably, a study enroling a large samples of ASD patients between the ages of 10 and 35 years found an impairment of anatomical connectivity for the whole age range in white matter structures involved in long-range intra-and interhemispheric communication (anterior corona radiate, right retrolenticular part of internal capsule and corpus callosum). 150 Although studies on anatomical connectivity focus on changes in white matter structures, functional magnetic resonance imaging studies can be used to investigate co-activation patterns during a given paradigm. Executive function has been shown to be decreased in ASD, 151 which appears to be present in adulthood as well as throughout development. [152] [153] [154] [155] Several studies examined functional connectivity in ASD patients during higher-order information processing, describing a pattern of reduced frontoparietal connectivity during response inhibition, 156 sentence comprehension 156, 157 and working memory tasks. 158, 159 Although initially hypothesized, 157 these changes do not seem to reflect a general functional underconnectivity in the brains of ASD patients, but an inability to effectively integrate cerebral networks to support complex information processing in a cognitive task. 143 Strikingly, variations in the BDNF genes have been shown to influence age-related decline in executive function, although results that show that decline happens more rapidly in Met allele carriers are admittedly not unanimous. 160, 161 Animal experiments hint at an impaired synaptic plasticity in the prefrontal cortex as a potential neurobiological mechanism mediating BDNF effects on executive functions. 162 Altogether, results derived from brain imaging and neuropsychology hint at an involvement of BDNF dysfunction in the impairment of executive functions in the context of a reduced anatomical and functional connectivity.
Preclinical models
Besides the research strategies mentioned above, the use of animal models is of great importance for determining the genotype-phenotype relationship of neurotrophins in the context of ASD. Advanced transgenic and recombinant technologies as well as the sequencing of the mouse genome have made the mouse to be the model of choice for many geneticists.
Not all human behaviours can be translated to animal models. However, by analytically observing and dissecting behaviour, it is possible to derive mouse models that reflect aberrant social interaction.
Consequently, study groups aimed at establishing behavioural tests thought to assess behavioural abnormalities in mouse models paralleling core autistic features such as aberrant social responses, repetitive behaviour or restricted interests. 163 Testing screens for social responses usually include assays for social approach and preference for social novelty, in which mice have a choice between social and nonsocial stimuli of different types. 164 Behavioural assays exist for both 'lower-order' motoric stereotypy and 'higher-order' responses reflecting, for example, restricted interests and strong resistance to environmental change. Whereas the 'lower-order' components can be tested, for example, by home cage observation, 165 'higher-order' motor functions can be evaluated, for example, in T-maze or water maze tasks. 164 As symptoms in autism spectrum disorders emerge early in childhood, valid mouse models of ASD should display behavioural phenotypes recapitulating the time course of disease onset. [166] [167] [168] One of the most common assays to assess behavioural abnormalities in early stages of development is the measurement of ultrasonic vocalization in mouse pups separated from their mothers as a test for altered emotional behaviour. [169] [170] [171] Social behaviour in the mouse model seems to be influenced by neurotrophins. Mice raised in a socially enriched environment display higher propensity to interact socially. Interestingly, it has been shown that these animals show higher NGF levels. These are further influenced by social status and higher BDNF levels in the brain. 163 Chen et al. 172 investigated the influence of the Val66Met polymorphism on anxietyrelated behaviour in a mouse model. Consistent with the findings mentioned above, mice with Met/Met allele (that consecutively leads to decreased neuronal secretion of BDNF) display more anxious behaviour in stressful settings. However, it has to be acknowledged that other behavioural paradigms-for example, sociability or repetitive behaviour-were not tested in this study. A more detailed characterization of the behavioural phenotypes relating to ASDspecific traits seems to be a promising goal for future research in this field.
Summary and future work
Owing to their pivotal role not only during neurodevelopment, but also in the regulation of mature synapto-and neuroplasticity, NTFs have been the focus of various studies on neuropsychiatric disorders and ASD. 51, 141, 173, 174 Most investigations in the context of NTFs in ASD have concentrated on the neurotrophin family. Various studies were able to show alterations in neurotrophin serum levels. Nonneurotrophic ASD susceptibility genes were shown not only to influence BDNF expression, but also to be regulated by BDNF signalling in a positive feedback loop. It could be speculated that genetic vulnerability for ASD might exert its influence at least in part through altered neurotrophin expression patterns. Reduced neurotrophin serum levels might in turn be responsible for typical features of cellular morphology and impaired neuronal functioning in ASD.
Some methodological limitations still have to be taken into consideration before interpreting of the results of the studies. Few studies have actually reported to control for circadian variation or neurodevelopmental trajectories of neurotrophin secretion. 82 In fact, to our knowledge, studies dealing with the question of whether ASD patients show any disturbances in the circadian rhythmicity of neurotrophin secretion do not exist. Hence, with the currently available data, an exact characterization of neurotrophin serum level alterations cannot be given.
As shown above, not only mature neurotrophin proteins but also their unconverted pro-forms are able to interact with Trk and p75 receptors. Due to the higher affinity of pro-neurotrophins to the p75 receptor, which is capable of mediating apoptosis, 56, 74 the ratio between mature and immature neurotrophins might influence cellular fate. Consequently, pathologies of the neurotrophin system might not only involve the overall level of the converted proteins, but also the level of the unconverted proforms, whereas dysfunctions of their converting enzymes might be key mediators of this process. Consequently, altered neurotrophin serum levels are hard to interpret without knowledge of their pro-form levels. Even normal neurotrophin serum levels might not rule out pathologies of the neurotrophin system. Accordingly, studies on the regional cerebral levels of mature and immature neurotrophins might help to elucidate the pathomechanisms here.
Moreover, solidification of evidence for significant interactions between ASD susceptibility genes and, for example, BDNF is still required. Histopathological studies might yield additional evidence.
Comparatively few studies have examined the role of non-neurotrophic NTFs and ASD. Because of its double role as potent immune suppressor and its influence on specification of developmental fate in embryogenesis, 89, 90 the TGF-b1 molecule is another promising candidate in this context. TGF-b1 might exert its effect by both functions. Immune suppression by the TGF-b is of high importance for the protection of the developing tissues; knock-out mice lacking one of the three TGF-b isoforms usually only survive several days or weeks. [175] [176] [177] Reduced TGF-b1 levels in autism might lead to defective immune suppression and in consequence to autoimmuneinduced neuronal loss. The influence of TGF-b signalling pathways on a cellular phenotype also seem to fit into another model of ASD pathophysiology: the Ras/Raf/ERK pathway-besides the growtharrest inducing Smad pathway the second-best described cascade-has been described as a potent inductor of change to cellular morphology. 89, 178 However, only two studies prompt speculations concerning altered TGF-b1 levels in ASD patients. 91, 92 A third was not able to show an association of TGF-b1 gene variants with ASD. 93 Additional studies with larger sample sizes are needed before drawing final conclusions.
Similarly, more in-depth studies on IGFs have to be carried out before interpreting the few studies on this molecule in the context of ASD. However, investigations on IGF-1, IGF-2 and the IGF-binding proteins have reported first promising results. Two studies successfully showed an association between elevated IGF-1 levels and head circumference, 99, 101 whereas a third even detected even lower IGF-1 levels in the autism group. 102 However, the discrepancies might be due to methodological limitations: Riikonen et al. 99 measured CSF levels and Mills et al. 101 serum levels, whereas Fall et al. 102 analysed urine samples. Head circumference in the ASD groups might also influence the results. As IGF-1 levels have been shown to be associated with total brain volume in animal experiments, 98 ,99 elevated IGF-1 levels might not necessarily be associated with autism but with head circumference/macrocephaly.
A majority of NTFs have not been investigated for their role in autism. Hence, the specificity of the reported alterations of NTF levels is hard to judge. Also, comparisons of reported NTF level changes in ASD with NTF levels in other psychiatric disorders are still scarce.
Finally, NTFs have a different impact on different neuronal sub-populations. Studies on NTF serum or CSF levels represent valuable exploratory approaches. Nonetheless, they can only provide sparse insight into the complex pathomechanisms on a cellular and histological level.
The combination of both neuroimaging and molecular biology has already shown some promising results in other areas of psychiatric research. 118, 120, 121 Due to its noninvasive character, a comparatively large sample size can be included. Moreover, longitudinal studies are possible as well. A correlation between genetics, neurochemistry and in vivo studies on brain structure and function may yield additional insight on the pathogenesis of autism.
The emerging understanding of the role of NTFs in autism will most likely affect diagnostic and therapeutic processes. Molecular screening might become a new valid diagnostic tool for early identification of ASD patients. 179 Both conventional and experimental therapies might benefit from an increased knowledge about NTF-related pathophysiology. A recent study has shown the BDNF Val66Met polymorphism to be associated with prolactine elevation caused by risperidone treatment in autistic patients. 180 Thus, knowledge about the BDNF genotype might help to limit prolactine elevation-associated side effects.
The development of NTF-specific therapeutic agents might provide causal therapeutic approaches. Based on the hypothesis of a hyperactivation of TrkB signalling in autism, the use of a TrkB partial agonist has been proposed as a novel therapy. 181 Although up to now, to our best knowledge, clinical studies on the potential of therapeutic agents interacting with NTF signalling have not been conducted, NTF-related signalling pathways appear as a promising candidate for therapeutic intervention in autism.
In summary, there is good evidence for the hypothesis that NTFs have an important role in the pathophysiology of autism. Further investigations in not only the molecular mechanisms, but also correlations of molecular parameters with histopathology and neuroimaging might be worthwhile pursuing for a more comprehensive understanding of the pathomechanisms underlying the complex ASDs.
